Pimavanserin: novel pharmacotherapy for Parkinson’s disease psychosis
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pimavanserin: novel pharmacotherapy for Parkinson’s disease psychosis
Authors
Keywords
-
Journal
Expert Opinion on Drug Discovery
Volume 13, Issue 1, Pages 103-110
Publisher
Informa UK Limited
Online
2017-10-19
DOI
10.1080/17460441.2018.1394838
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dorsal-to-Ventral Shift in Midbrain Dopaminergic Projections and Increased Thalamic/Raphe Serotonergic Function in Early Parkinson Disease
- (2015) J. Joutsa et al. JOURNAL OF NUCLEAR MEDICINE
- Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis
- (2015) Clive Ballard et al. Journal of the American Medical Directors Association
- Parkinson Disease Psychosis: Update
- (2014) J. H. Friedman BEHAVIOURAL NEUROLOGY
- On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
- (2014) Uli Hacksell et al. NEUROCHEMICAL RESEARCH
- Antipsychotic efficacy and good tolerability in a Phase III placebo-controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP-103-020)
- (2013) Clive Ballard et al. Alzheimers & Dementia
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
- (2013) Jeffrey Cummings et al. LANCET
- Mirtazapine improves visual hallucinations in Parkinson's disease: a case report
- (2013) Kenji Tagai et al. Psychogeriatrics
- The serotonergic system in motor and non-motor manifestations of Parkinson’s disease
- (2013) Philippe Huot et al. EXPERIMENTAL BRAIN RESEARCH
- Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer’s disease
- (2012) Diana L. Price et al. BEHAVIOURAL PHARMACOLOGY
- Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: A prospective study
- (2012) Ronald B. Postuma et al. MOVEMENT DISORDERS
- Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson's disease psychosis
- (2012) Tiffini Voss et al. PARKINSONISM & RELATED DISORDERS
- Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day
- (2012) Herbert Y. Meltzer et al. SCHIZOPHRENIA RESEARCH
- Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
- (2011) Daniel Weintraub ARCHIVES OF NEUROLOGY
- Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinsonʼs disease
- (2011) Krista McFarland et al. BEHAVIOURAL PHARMACOLOGY
- Testing an aetiological model of visual hallucinations in Parkinson's disease
- (2011) D. A. Gallagher et al. BRAIN
- Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects
- (2011) Magdalena Nord et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- A 12-Year Population-Based Study of Psychosis in Parkinson Disease
- (2010) Elin B. Forsaa et al. ARCHIVES OF NEUROLOGY
- Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
- (2010) Benedicte Ballanger et al. ARCHIVES OF NEUROLOGY
- Relationships between age and late progression of Parkinson's disease: a clinico-pathological study
- (2010) P. A. Kempster et al. BRAIN
- Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data
- (2010) Teus van Laar et al. CNS Neuroscience & Therapeutics
- Increased 5-HT2Areceptors in the temporal cortex of parkinsonian patients with visual hallucinations
- (2010) Philippe Huot et al. MOVEMENT DISORDERS
- What predicts mortality in Parkinson disease?: A prospective population-based long-term study
- (2010) E. B. Forsaa et al. NEUROLOGY
- Quetiapine in the treatment of psychosis in Parkinson’s disease
- (2010) Paul Shotbolt et al. Therapeutic Advances in Neurological Disorders
- Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
- (2009) Daniel Ecker et al. BMC Neurology
- Admission of Parkinsonian patients to a neurological ward in a community hospital
- (2009) Colin Klein et al. JOURNAL OF NEURAL TRANSMISSION
- Epidemiology of psychosis in Parkinson's disease
- (2009) Gilles Fénelon et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis
- (2009) Herbert Y Meltzer et al. NEUROPSYCHOPHARMACOLOGY
- Impact of standard of care for psychosis in Parkinson disease
- (2008) T R Thomsen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Parkinson's disease: clinical features and diagnosis
- (2008) J Jankovic JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease
- (2008) M.E. Kalaitzakis et al. PARKINSONISM & RELATED DISORDERS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started